Risankizumab Dosage

Medically reviewed by Drugs.com. Last updated on Feb 20, 2024.

Usual Adult Dose for Psoriatic Arthritis

150 mg (two 75 mg injections) subcutaneously at Week 0, Week 4, and every 12 weeks thereafter

Comments:

• Evaluate patients for tuberculosis (TB) infection prior to initiating this drug.
• In psoriatic arthritis this drug can be administered alone or in combination with non-biologic disease modifying antirheumatic drugs (DMARDs).

Use(s):

• For the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
• For the treatment of active psoriatic arthritis

Usual Adult Dose for Plaque Psoriasis

150 mg (two 75 mg injections) subcutaneously at Week 0, Week 4, and every 12 weeks thereafter

Comments:

• Evaluate patients for tuberculosis (TB) infection prior to initiating this drug.
• In psoriatic arthritis this drug can be administered alone or in combination with non-biologic disease modifying antirheumatic drugs (DMARDs).

Use(s):

• For the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
• For the treatment of active psoriatic arthritis

Usual Adult Dose for Crohn's Disease - Acute

Induction dose: 600 mg by IV infusion over at least one hour at Week 0, Week 4, and Week 8
Maintenance dose: 180 mg or 360 mg subcutaneously at Week 12, and every 8 weeks thereafter.

Comments:

• Use the lowest effective dosage to maintain therapeutic response.
• Obtain liver enzymes and bilirubin prior to treatment initiation.

Use: Moderately to severely active Crohn's disease

Usual Adult Dose for Crohn's Disease - Maintenance

Induction dose: 600 mg by IV infusion over at least one hour at Week 0, Week 4, and Week 8
Maintenance dose: 180 mg or 360 mg subcutaneously at Week 12, and every 8 weeks thereafter.

Comments:

• Use the lowest effective dosage to maintain therapeutic response.
• Obtain liver enzymes and bilirubin prior to treatment initiation.

Use: Moderately to severely active Crohn's disease

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

The US FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for this drug. It requires a medication guide to assure safe use. For additional information: www.fda.gov/drugs/drug-safety-and-availability/medication-guides

CONTRAINDICATIONS:

• History of serious hypersensitivity reaction to this drug or any of the excipients

Safety and efficacy have not been established in patients younger than 18 years.

Report suspected adverse reactions at www.fda.gov/medwatch

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
PRIOR TO TREATMENT INITIATION:

• Evaluate patients for tuberculosis infection.
• Complete all age-appropriate vaccination according to immunization guidelines.
• If treating Crohn's disease, obtain liver enzymes and bilirubin levels.

GENERAL CONSIDERATIONS:

• This drug is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject after training in subcutaneous injection technique.
• Visually inspect the prefilled syringe for particulate matter and discoloration prior to administration. It should be a colorless to slightly yellow and clear to slightly opalescent solution. It may contain a few translucent to white particles. Do not use if the solution contains large particles or is cloudy or discolored.
• Inject 2 separate 75 mg single-dose prefilled syringes for the full 150 mg dose.
• Discard prefilled syringes after use; do not reuse.
• Administer the injections at different anatomic locations (e.g., thigh, abdomen) and not into areas where the skin is tender, bruised, erythematous, indurated, or affected by psoriasis. Administration into the upper outer arm may only be performed by a healthcare professional or caregiver.
• If a dose is missed, administer it as soon as possible; thereafter, resume dosing at the regular scheduled time.
• Refer to the manufacturer's prescribing information for more detailed instructions on the preparation and administration of this drug.

Storage requirements:

• Store unopened product in a refrigerator at 2C to 8C (36F to 46 F).
• Do not freeze.
• Do not shake.
• Keep the prefilled syringes in the outer carton to protect from light.
• Not made with natural rubber latex.

Monitor:

• For signs and symptoms of TB during and after treatment
• Liver enzymes and bilirubin at baseline, during induction, and up to at least 12 weeks of treatment of Crohn's disease

Patient advice:

• Read the Patient Information and Instructions for Use.

Frequently asked questions

• Does Skyrizi cause cancer?
• Skyrizi vs Humira for plaque psoriasis - How do they compare?
• Who makes Skyrizi and where is it made?
• Is Skyrizi approved for treating psoriatic arthritis?
• Skyrizi vs Ilumya. What’s the difference?
• What are the new drugs for plaque psoriasis?

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer